About This Ipamorelin Digest
What this site is, what it is not, and the editorial standard behind every cited claim.
What this site is
Pharmacy Ipamorelin publishes plain-English summaries of the peer-reviewed research literature on ipamorelin, read deliberately through one lens: pharmacokinetics — how the peptide enters, moves through, and leaves the body, and the single growth-hormone pulse that follows. No clinic stands behind it and no clinician is on staff; it gives no medical advice, and it makes, stocks, and sells nothing. Its work is a reading of published science.
About the name — and the word 'pharmacy'
The word 'pharmacy' in this domain is editorial framing, not a description of any service. This site is not a pharmacy. It stocks nothing, dispenses nothing, fills no orders, and is not a place to obtain ipamorelin. Ipamorelin is not an approved or stocked pharmacy medication anywhere [2]. We chose the kinetics lens because a pharmacy's core competence — knowing exactly how a substance behaves once it is in the body — is precisely what the published ipamorelin record can speak to: half-life, clearance, the time-course of the GH response [1]. That is the position this publisher occupies relative to the literature, and nothing more.
Is ipamorelin fda approved
No. Ipamorelin is not FDA approved as a drug for any indication, and it has never been approved by any regulator anywhere [2]. It was investigated for postoperative ileus (NCT00672074), but that Phase 2 trial missed its primary endpoint and no further development followed [2]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug-substances list and reviewed it at an October 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is marketed only as a research chemical, and it is banned in sport at all times under the WADA Prohibited List (category S2) [2].
Our editorial standard
Every quantitative claim on this site — every dose, half-life, percentage, and p-value — maps to a numbered citation on the references page, drawn from PubMed, peer-reviewed journals, and ClinicalTrials.gov. Where the human evidence is thin, we say so plainly rather than dressing up rodent data as proof. Where effects are reported only by the research-use community, we label them anecdotal and never attach a dose. We do not name drug brands, we do not recommend a human dose, and we do not tell anyone what to do. The aim is a faithful, readable map of what the studies actually measured.